MA49513A - Vecteurs viraux recombinés à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines - Google Patents

Vecteurs viraux recombinés à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines

Info

Publication number
MA49513A
MA49513A MA049513A MA49513A MA49513A MA 49513 A MA49513 A MA 49513A MA 049513 A MA049513 A MA 049513A MA 49513 A MA49513 A MA 49513A MA 49513 A MA49513 A MA 49513A
Authority
MA
Morocco
Prior art keywords
recombinated
tropism
modified
viral vectors
human cells
Prior art date
Application number
MA049513A
Other languages
English (en)
Other versions
MA49513B1 (fr
Inventor
Christos Kyratsous
Andrew J Murphy
Leah Sabin
Cheng Wang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA49513A publication Critical patent/MA49513A/fr
Publication of MA49513B1 publication Critical patent/MA49513B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA49513A 2017-06-27 2018-06-27 Vecteurs viraux recombinants au tropisme modifié et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines MA49513B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762525704P 2017-06-27 2017-06-27
PCT/US2018/039874 WO2019006043A1 (fr) 2017-06-27 2018-06-27 Vecteurs viraux recombinés à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines

Publications (2)

Publication Number Publication Date
MA49513A true MA49513A (fr) 2020-05-06
MA49513B1 MA49513B1 (fr) 2024-05-31

Family

ID=63080487

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49513A MA49513B1 (fr) 2017-06-27 2018-06-27 Vecteurs viraux recombinants au tropisme modifié et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines

Country Status (28)

Country Link
US (1) US20200140491A1 (fr)
EP (2) EP3645551B1 (fr)
JP (4) JP7372154B2 (fr)
KR (3) KR102877478B1 (fr)
CN (2) CN110799524A (fr)
AU (3) AU2018290882B2 (fr)
CA (1) CA3066947A1 (fr)
CL (3) CL2019003842A1 (fr)
CO (1) CO2019014683A2 (fr)
DK (1) DK3645551T5 (fr)
ES (1) ES2978295T3 (fr)
FI (1) FI3645551T3 (fr)
HR (1) HRP20240773T1 (fr)
HU (1) HUE066398T2 (fr)
IL (2) IL271573B2 (fr)
LT (1) LT3645551T (fr)
MA (1) MA49513B1 (fr)
MD (1) MD3645551T2 (fr)
MX (2) MX2020000244A (fr)
PE (1) PE20200488A1 (fr)
PH (1) PH12019550266A1 (fr)
PL (1) PL3645551T3 (fr)
PT (1) PT3645551T (fr)
RS (1) RS65569B1 (fr)
SG (1) SG11201911610TA (fr)
SI (1) SI3645551T1 (fr)
SM (1) SMT202400189T1 (fr)
WO (1) WO2019006043A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN113166208B (zh) 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
EP3736330A1 (fr) * 2019-05-08 2020-11-11 European Molecular Biology Laboratory Particules modifiées du virus adéno-associé (aav) pour la thérapie génique
AU2020283537A1 (en) 2019-05-24 2021-12-16 Regeneron Pharmaceuticals, Inc. Modified viral particles and uses thereof
US12630842B2 (en) 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
MX2023005446A (es) 2020-11-11 2023-07-18 European Molecular Biology Laboratory Particulas virales modificadas para terapia genica.
MX2023013041A (es) * 2021-05-05 2024-01-05 Janssen Biotech Inc Redireccionamiento universal de hsv oncolítico.
CN115873987A (zh) * 2021-09-30 2023-03-31 北京五加和基因科技有限公司 检测腺相关病毒载体感染滴度的方法和试剂盒
EP4426716A1 (fr) 2021-11-02 2024-09-11 Voyager Therapeutics, Inc. Variants capsidiques de vaa et utilisations associées
MX2024005314A (es) 2021-11-04 2024-05-17 Regeneron Pharma Particulas virales redirigidas a musculo esqueletico.
CN114213505B (zh) * 2021-12-10 2022-09-20 和元生物技术（上海）股份有限公司 一种适用于特异感染u87-mg细胞的腺相关病毒突变体
US20250161486A1 (en) * 2022-02-22 2025-05-22 The University Of North Carolina At Chapel Hill Chimeric neurotropic aav capsids
CN115044615B (zh) * 2022-04-28 2025-09-05 三峡大学 一种靶向感染乳腺癌细胞的aav载体及应用
AU2023269134A1 (en) 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
EP4522272A4 (fr) * 2022-05-11 2026-07-29 Childrens Hospital Philadelphia Vecteurs viraux adéno-associés pour cibler des structures cérébrales profondes
AU2023267474A1 (en) * 2022-05-13 2024-12-05 Children's Medical Research Institute Adeno-associated virus capsids
MA71631A (fr) 2022-07-29 2025-05-30 Regeneron Pharmaceuticals, Inc. Particules virales reciblées vers le récepteur 1 de transferrine
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
JP2026500017A (ja) * 2022-12-16 2026-01-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａａｖ粒子に結合する抗原結合分子及びその使用
WO2024131982A1 (fr) * 2022-12-23 2024-06-27 北京大学宁波海洋药物研究院 Conjugué protéine capsidique-anticorps, virus modifié, combinaison pharmaceutique et utilisation
WO2024173248A1 (fr) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Traitement de troubles musculaires avec des anticorps anti-cacng1 humains
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
CN118955652A (zh) * 2023-05-15 2024-11-15 杭州新昶基因技术有限公司 腺相关病毒衣壳蛋白、包含其的腺相关病毒及应用
WO2025042428A1 (fr) * 2023-08-18 2025-02-27 Regeneron Pharmaceuticals, Inc. Molécules bispécifiques de liaison à l'antigène et leurs utilisations
WO2025072501A2 (fr) * 2023-09-26 2025-04-03 The Trustees Of Princeton University Procédé de conversion de farnésyl pyrophosphate synthase en géranyl pyrophosphate synthase
WO2025084336A1 (fr) 2023-10-17 2025-04-24 国立大学法人大阪大学 Molécule pouvant se lier simultanément à une capside de vaa et à un récepteur cible
AU2025207849A1 (en) 2024-01-11 2026-07-16 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to nervous system tissues
WO2025160340A2 (fr) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Immunosuppression combinée pour inhiber une réponse immunitaire et pour permettre une administration et une réadministration d'immunogène
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2026025058A1 (fr) 2024-07-25 2026-01-29 Regeneron Pharmaceuticals, Inc. Particules virales d'aav reciblées sur des cellules cancéreuses exprimant le r-egf
WO2026039325A2 (fr) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Gènes mtm1 modifiés et utilisations associées
CN119039401B (zh) * 2024-08-19 2025-04-11 广州派真生物技术有限公司 腺相关病毒突变体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261554B1 (en) 1995-07-25 2001-07-17 Introgene B.V. Compositions for targeted gene delivery
CN1304316A (zh) 1998-02-06 2001-07-18 亚拉巴马大学伯明翰分校研究基金会 在纤维结的hi环中含有异源肽表位的腺病毒载体
DE19849643A1 (de) * 1998-10-29 2000-05-04 Deutsches Krebsforsch An das AAV-Kapsid bindender, den Zelltropismus verändernder Antikörper und Verfahren zum gerichteten Gentransfer
DE19933719A1 (de) * 1999-07-19 2001-01-25 Medigene Ag Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
US20050233307A1 (en) * 2002-09-12 2005-10-20 Kyle Gee Site-specific labeling of affinity tags in fusion proteins
US7273835B2 (en) * 2004-08-04 2007-09-25 Honeywell International Inc. Azeotrope-like compositions of difluoromethane
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2012122A1 (fr) 2007-07-06 2009-01-07 Medigene AG Protéines structurelles de parvovirus muté
EP2158211B1 (fr) 2007-05-31 2016-08-10 Medigene AG Protéine structurale mutée d'un parvovirus
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
WO2011072204A1 (fr) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Souris fabriquant des anticorps à chaînes lourdes
FR2955773B1 (fr) * 2010-02-01 2017-05-26 Commissariat Energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
KR102298579B1 (ko) * 2013-05-21 2021-09-07 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US10370432B2 (en) * 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
DE102015207516A1 (de) * 2015-04-23 2016-10-27 Paul-Ehrlich-Institut Bundesamt Für Sera Und Impfstoffe Kopplung von Proteinen von Interesse (POI) mit viralen Vektoren mittels Intein-vermittelten Proteinspleißens

Also Published As

Publication number Publication date
ES2978295T3 (es) 2024-09-10
DK3645551T3 (da) 2024-05-06
KR20200022434A (ko) 2020-03-03
CN117051045B (zh) 2025-04-08
PE20200488A1 (es) 2020-03-03
AU2018290882A1 (en) 2020-01-16
CL2019003842A1 (es) 2020-07-24
MX2023009050A (es) 2023-08-10
BR112019027854A2 (pt) 2020-07-07
SG11201911610TA (en) 2020-01-30
HUE066398T2 (hu) 2024-07-28
CN110799524A (zh) 2020-02-14
WO2019006043A1 (fr) 2019-01-03
MX2020000244A (es) 2020-09-28
RU2020101279A (ru) 2021-07-27
PL3645551T3 (pl) 2024-07-01
HRP20240773T1 (hr) 2024-09-13
EP3645551A1 (fr) 2020-05-06
CO2019014683A2 (es) 2020-01-17
US20200140491A1 (en) 2020-05-07
DK3645551T5 (da) 2024-08-26
LT3645551T (lt) 2024-05-10
KR20240149451A (ko) 2024-10-14
PT3645551T (pt) 2024-05-13
EP3645551B1 (fr) 2024-03-13
MA49513B1 (fr) 2024-05-31
IL317938A (en) 2025-02-01
RS65569B1 (sr) 2024-06-28
JP2020529196A (ja) 2020-10-08
PH12019550266A1 (en) 2021-01-11
IL271573B1 (en) 2025-02-01
BR122023021213A2 (pt) 2024-02-20
SMT202400189T1 (it) 2024-07-09
CA3066947A1 (fr) 2019-01-03
JP2024036644A (ja) 2024-03-15
EP4372008A2 (fr) 2024-05-22
JP7372154B2 (ja) 2023-10-31
AU2023206143A1 (en) 2023-08-10
MD3645551T2 (ro) 2024-08-31
SI3645551T1 (sl) 2024-06-28
RU2020101279A3 (fr) 2022-02-04
AU2023206143B2 (en) 2025-10-30
IL271573B2 (en) 2025-06-01
FI3645551T3 (fi) 2024-05-03
CL2024001376A1 (es) 2024-10-25
CN117051045A (zh) 2023-11-14
JP2026042952A (ja) 2026-03-11
JP7851839B2 (ja) 2026-04-27
JP2022183228A (ja) 2022-12-08
AU2018290882B2 (en) 2023-07-27
EP4372008A3 (fr) 2024-07-31
CL2020003343A1 (es) 2021-06-25
AU2026200511A1 (en) 2026-02-12
IL271573A (en) 2020-02-27
KR102714347B1 (ko) 2024-10-14
KR20250160215A (ko) 2025-11-11
KR102877478B1 (ko) 2025-10-29

Similar Documents

Publication Publication Date Title
MA49514A (fr) Particules virales recombinantes avec tropisme modifié, et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines
IL271573A (en) Recombinant viral vectors that have undergone a tropism change and their uses for the targeted introduction of genetic material into human cells
EP3635108A4 (fr) Agents d'activation destinés à la transfection de cellules et/ou la production de vecteur raav améliorées
EP3662083A4 (fr) Indexation spatiale de matériel génétique et préparation de pharmacothèque à l'aide de billes d'hydrogel et de cellules d'écoulement
MA51842A (fr) Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion
EP3728568A4 (fr) Procédés et compositions pour l'administration de vecteurs viraux à travers la barrière hémato-encéphalique
EP3642353A4 (fr) Évaluation du risque de complication d'une greffe avec l'adn acellulaire total
IL290132A (en) Materials and methods for treating friedreich's ataxia
EP3414787A4 (fr) Matériaux d'électrode prélithiés et cellules les comprenant
EP3443081A4 (fr) Répresseurs à base de crispr/cas9 pour inactiver des cibles géniques in vivo et procédés d'utilisation
MA55313A (fr) Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques du facteur viii
EP3604524A4 (fr) Nouvelle technique de clonage direct de grands fragments génomiques et ensemble multi-moléculaire d'adn
EP3835418A4 (fr) Nouvelle protéine associée aux crispr et utilisation de celle-ci
MA46111A (fr) Bactéries génétiquement modifiées sécrétant des protéines thérapeutiques et procédés d'utilisation de celles-ci
EP3413887A4 (fr) Intermédiaires utilisés dans la synthèse d'éribuline et procédés de synthèse associés
EP3791327A4 (fr) Classement et recommandation d'éléments de généalogie
EP3880827A4 (fr) Compositions et procédés pour induire la différenciation d'une cellule capillaire
EP3724883A4 (fr) Détection de délétions et de variations de nombre de copies dans des séquences d'adn
EP3697914C0 (fr) Vecteurs destinés au traitement de l'ataxie de friedreich
EP3679050A4 (fr) Procédés et compositions destinés à l'expression améliorée de protéines recombinantes
EP3601572A4 (fr) Construction d'expression de protéine et procédés associés
EP3455360A4 (fr) Constructions d'adn pour la fabrication de polypeptides biothérapeutiques pour utilisation dans des vaccins et des agents thérapeutiques pour animaux
EP3870705A4 (fr) Amélioration de la qualité d'adn acellulaire
EP3870718A4 (fr) Procédés et utilisations de l'introduction de mutations dans un matériel génétique pour l'assemblage du génome
EP3454913A4 (fr) Conjugué thérapeutique de ciblage osseux et méthodes de fabrication et d'utilisation de celui-ci